Skip to main content
main-content

EASD 58th Annual Meeting 2022

September 20 – September 23

EASD 2022 highlights

Overweight women have examination at dietitian-nutritionist's office (symbolic image with model)

23-09-2022 | EASD 2022 | Conference coverage | News

ADA/EASD hyperglycemia management consensus update strengthens holistic care

The latest update to the ADA and EASD hyperglycemia management consensus report places a strong emphasis on holistic, person-centered care for type 2 diabetes.

Girl with CGM

21-09-2022 | EASD 2022 | Conference coverage | News

Skin reactions rarely lead to diabetes device discontinuation

Skin reactions to glucose monitors and insulin pumps occur in more than a quarter of users but only occasionally result in device discontinuation, research shows.

Illustration showing CGM communicating with Insulin Pump

20-09-2022 | EASD 2022 | Conference coverage | News

​​​​​​​Fully closed-loop control boosts TIR in insulin-treated type 2 diabetes

A fully closed-loop insulin delivery system markedly increases time in range for people with insulin-treated type 2 diabetes, shows a small randomized crossover trial.

EASD 2022 research news

23-09-2022 | EASD 2022 | Conference coverage | News

​​​​​​​Better diabetes self-care during adolescence could improve glycemic control trajectory

Among adolescents with type 1 diabetes, those with better self-care are more likely to have favorable glycated hemoglobin trajectories into early adulthood, study findings suggest.

23-09-2022 | EASD 2022 | Conference coverage | News

Topical esmolol hydrochloride may aid healing of diabetic foot ulcers

The use of esmolol hydrochloride in adults with diabetic foot ulcer improves wound healing and may constitute a novel treatment option, suggests research reported at the 58th EASD Annual Meeting in Stockholm, Sweden.

23-09-2022 | EASD 2022 | Conference coverage | News

​​​​​​​ReTUNE analysis backs ‘personal fat threshold’ concept

The findings of the ReTUNE study show that losing a substantial amount of weight can reverse type 2 diabetes even in people who are only mildly overweight.

23-09-2022 | EASD 2022 | Conference coverage | News

Bolus timing requires more attention in people using advanced technologies for type 1 diabetes

Delayed prandial insulin boluses are common in people using advanced technologies for the management of type 1 diabetes and are associated with adverse glycemic outcomes, suggest real-world study results.

23-09-2022 | EASD 2022 | Conference coverage | News

Degree of autoimmunity impacts CVD risk in LADA

Research suggests that people with latent autoimmune diabetes in adults and high levels of glutamic acid decarboxylase antibodies have a higher risk for cardiovascular disease than those with lower autoantibody levels.

23-09-2022 | EASD 2022 | Conference coverage | News

Childhood body size modifies diabetes risk in adulthood

The highest risk for type 2 diabetes occurs in people who progress from a low body size in childhood to a high body size in adulthood, shows an analysis of data from the UK Biobank.

22-09-2022 | EASD 2022 | Conference coverage | News

High-intensity exercise may be beneficial for people with impaired hypoglycemia awareness

Findings from the HIT4HYPOS trial suggest that a high-intensity exercise program may improve hormonal and symptomatic responses to hypoglycemia among people with type 1 diabetes and impaired awareness of hypoglycemia.

22-09-2022 | EASD 2022 | Conference coverage | News

Microalbuminuria in pregnancy forecasts adverse outcomes

Women with type 1 diabetes who have microalbuminuria at the time of pregnancy have an increased risk for adverse pregnancy outcomes in the short term and for diabetes complications in the long term, shows research.

22-09-2022 | EASD 2022 | Conference coverage | News

Support for tailored genetic counseling in people with incidentally discovered MODY mutations

Mutations in HNF1A and HNF4A are less likely to be associated with a diagnosis of maturity-onset diabetes of the young when discovered incidentally versus in a clinically selected cohort, research suggests.

22-09-2022 | EASD 2022 | Conference coverage | News

​​​​​​​Psychologic resilience tied to glycemic control after type 1 diabetes diagnosis

Researchers find psychologic resilience to be predictive of glycated hemoglobin levels in the 3 years after type 1 diabetes diagnosis.

More research news from EASD 2022

22-09-2022 | EASD 2022 | Conference coverage | News

Model could predict severe hypoglycemia risk in people with type 2 diabetes

A number of factors are associated with severe hypoglycemia risk in people with type 2 diabetes treated with insulin or sulfonylureas, suggests research reported at the 58th EASD Annual Meeting in Stockholm, Sweden.

21-09-2022 | EASD 2022 | Conference coverage | News

isCGM benefits sustained for at least 2 years

The improved glycemic control gained from use of intermittently scanned continuous glucose monitoring is sustained for at least 2 years in people with type 1 diabetes, show real-world data.

21-09-2022 | EASD 2022 | Conference coverage | News

C-peptide may be better than CRP for predicting cardiovascular risk in type 2 diabetes

Among people with early type 2 diabetes, levels of C-peptide are more strongly associated with the risk for future cardiovascular events than levels of C-reactive protein, research suggests.

21-09-2022 | EASD 2022 | Conference coverage | News

Libre upgrade illustrates power of hypoglycemia alerts

Gaining the use of a low blood glucose alert by switching from the FreeStyle Libre 1 to 2 reduces the amount of time people with type 1 diabetes spend in hypoglycemia, report researchers.

20-09-2022 | EASD 2022 | Conference coverage | News

Freestyle Libre cuts acute complication risk in insulin-treated type 2 diabetes

People taking basal insulin to treat type 2 diabetes experience a significant reduction in the risk for acute complications, which is sustained for at least 2 years after initiating use of the Freestyle Libre, say French researchers.

20-09-2022 | EASD 2022 | Conference coverage | News

Fatty liver index may predict mortality, CVD risk in people with type 1 diabetes

Hepatic steatosis, measured by the fatty liver index, is associated with an increased risk for mortality and cardiovascular disease among people with type 1 diabetes, research suggests.

20-09-2022 | EASD 2022 | Conference coverage | News

Insulin pump delivery may reduce fatty liver risk in type 1 diabetes

Using an insulin pump rather than multiple daily injections may help protect people with type 1 diabetes from developing fatty liver disease, report researchers.